CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...

Philadelphia, November 16, 2023 – Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, ...

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of ...

Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival PURPOSE: CD20 can be expressed in Hodgkin ...

AbbVie has fired back in the fierce fight for the CD20 bispecific market. Phase 1/2 data show AbbVie and Genmab’s epcoritamab triggers responses in heavily pretreated blood cancer patients, although ...

As a previous phase I clinical trial involving 15 infusions of unarmed anti-CD3-activated T cells (ATC), IL-2 and granulocyte macrophage colony-stimulating factor (GM-CSF) after HDC and SCT resulted ...

Please provide your email address to receive an email when new articles are posted on . Black patients with MS or neuromyelitis optica spectrum disorder experienced faster repopulation of B cells 6 to ...

Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS ...